Publication | Closed Access

Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways

Cancer ResearchOncologyOncogenic AgentMedicineFisetin InhibitsCancer Cell BiologyPathologyCancer BiologyErk1/2 Signaling PathwaysPharmacologyCell SignalingTumor Biology